The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
Open accessAbstract
Background: Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cells offer an ‘off-the-shelf’ CAR T-cell product, broadening access and applicability. UCART19 is an innovative genome-edited donor-derived allogeneic CAR T-cell product investigated in children and adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL). Methods: We enrolled paediatric or adult patients in two on-going phase I clinical trials to evaluate the safety and antileukaemic activity of UCART19. Patients underwent lymphodepletion with fludarabine and cyclophosphamide ± alemtuzumab, then children received UCART19 at 1·1 to 2·3×106 cells/kg and adults received UCART19 doses of 6×106, 6–8×107 or 1·8–2·4×108 cells in a dose-escalation study. These studies were registered at Clinicaltrials.gov (NCT02808442 and NCT02746952). Results: 7 children and 14 adults were enrolled in the two studies and received UCART19. Cytokine release syndrome (CRS) was the most common adverse event observed in 19 patients (91%); three (14%) had grade 3–4 CRS. Other adverse events were grade 1 or 2 neurotoxicity in eight patients (38%), grade 1 acute skin graft-versus-host disease in two patients (10%) and grade 4 prolonged cytopenia in six patients (29%). Two treatment-related deaths occurred; one caused by neutropenic sepsis in a patient with concurrent CRS and one from pulmonary haemorrhage in a patient with persistent cytopenia. The rate of complete remission or complete remission with incomplete hematologic recovery at day 28 post-infusion was 67%. Patients not receiving alemtuzumab (n=4 patients) showed no UCART19 expansion or antileukaemic activity. Interpretation: UCART19 exhibited in vivo expansion and anti-leukaemic activity with a manageable safety profile in heavily pretreated paediatric and adult patients with relapsed or refractory B-cell ALL. Funding: Servier
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-793141 · Cited by 1,156
Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016
Cited by
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 658
CAR T therapy beyond cancer: the evolution of a living drug
Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A., & June, C. H. (2023) · Nature · doi:10.1038/s41586-023-06243-w · Cited by 504
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 373
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Dimitri, A., Herbst, F., & Fraietta, J. A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01559-z · Cited by 352
Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia
Chiesa, R., Georgiadis, C., Syed, F., Zhan, H., Etuk, A., Gkazi, S. A., Preece, R., Ottaviano, G., Braybrook, T., Chu, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2300709 · Cited by 340
Self-citation
Metadata
- Authors
- Benjamin, R., Graham, C., Yallop, D., Jozwik, A., Mirci-Danicar, O. C., Lucchini, G., Pinner, D., Jain, N., Kantarjian, H., Boissel, N., Maus, M. V., Frigault, M. J., Baruchel, A., Mohty, M., Gianella-Borradori, A., Binlich, F., Balandraud, S., Vitry, F., Thomas, E., Philippe, A., Fouliard, S., Dupouy, S., Marchiq, I., Almena-Carrasco, M., Ferry, N., Arnould, S., Konto, C., Veys, P., Qasim, W., Benjamin, R., Graham, C., Yallop, D., Jozwik, A., Pagliuca, A., Mufti, G., Patten, P., Kassam, S., Devereux, S., Kazmi, M., Cuthill, K., Potter, V., Kuhnl, A., Metaxa, V., Bonganay, L., Stewart, O., Ellard, R., Catt, L., Lewis, J., Farzaneh, F., Chappell, J., Mason, A., Chu, V., Dunlop, A., Saleem, A., Cheung, G., Munro, H., Giemza, E., Qasim, W., Veys, P., Ciocarlie, O., Lucchini, G., Pinner, D., Chu, J., Amrolia, P., Rao, K., Chiesa, R., Silva, J., Hill, A., Finch, M., Young, L., Hara, H., Samarasinghe, S., Rao, A., Vora, A., Gilmour, K., Rivat, C., Murphy, C., Ahsan, G., Said Shamsah, R., James, J., Inglott, S., Wright, G., Adams, S., Izotova, N., Jain, N., Konopleva, M., Wierda, W., Jabbour, E., Kantarjian, H., Kebrieai, P., Jones, E., McGee, K., Maus, M., Frigault, M., Brown, J., Toncheva, V., Casey, K., Hock, H., McKeown, M. A., Mathews, R., Spitzer, T., Boissel, N., Raffoux, E., Lengliné, E., Itzykson, R., Rabian, F., Larghero, J., Madelaine, I., Azoulay, E., Clappier, E., Caillat-Zucman, S., Meunier, M., Celli-Lebras, K., Tremorin, M.-T., Baruchel, A., Yakouben, K., Mechinaud-Heloury, F., Grain, A., Alimi, A., Roupret, J., Chaillou, D., Larghero, J., Madelaine, I., Cavé, H., Caye-Eude, A., Fenneteau, O., Lainey, E., Naudin, J., Mohty, M., Brissot, E., Dulery, R., Malard, F., Mediavilla, C., Bonnin, A., Vekhoff, A., Ledraa, T., Larghero, J., & Daguenel-Nguyen, A.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 396
- Issue
- 10266
- Pages
- 1885-1894
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3113171896
- Cited by
- 368
- References
- 19
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. https://app.cochat.ai/papers/10.1016/s0140-6736(20)32334-5
- The paper
- Benjamin, R., Graham, C., Yallop, D., Jozwik, A., Mirci-Danicar, O. C., Lucchini, G., Pinner, D., Jain, N., Kantarjian, H., Boissel, N., Maus, M. V., Frigault, M. J., Baruchel, A., Mohty, M., Gianella-Borradori, A., Binlich, F., Balandraud, S., Vitry, F., Thomas, E., . . . Daguenel-Nguyen, A. (2020). Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. The Lancet. https://doi.org/10.1016/s0140-6736(20)32334-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.